Available Technologies
# of Displayed Technologies: 5 / 5
Applied Category Filter (Click To Remove): Small Molecules
Dual Androgen Receptor/AKR1C3 Inhibitors for Prostate Cancer
TS-062605 — The Need:
Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…
- College: College of Pharmacy
- Inventors: Li, Pui-Kai "Tom"; Cheng, Xiaolin; Kong, Xiaotian; Xing, Enming
- Licensing Officer: Schworer, Adam
An Orally Active, Selective Inhibitor of CD4+ T-Cell Activation That Blunts Left-Ventricular Remodeling and Improves Cardiac Function during Chronic Heart Failure
TS-057777 —
A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).
HF afflicts ~6.5 million adults in US with 50% mortality in first 5 years. It has an estimated market size of $4.2B USD in US alone with a forecasted CAGR of 23% from 2018-2028. Current HF treatments are mostly aimed at alleviating symptoms rather than treatment, resulting in progressive cardiac d…
- College: College of Medicine (COM)
- Inventors: Bansal, Shyam; Gumina, Richard
- Licensing Officer: He, Panqing
Oral cancer chemopreventive rinse
TS-037788 — Rinses with sustained contact time and field coverage have been developed to prevent oral cancer.
Oral cancer affects nearly 50,000 Americans each year and has a five year survival rate of 57%. Often, oral cancer is only discovered when it has metastasized, as it does not present recognizable symptoms, and it has a high risk of producing secondary tumors. Oral squamous cell carcinoma (OSCC), a…
- College: College of Dentistry
- Inventors: Mallery, Susan; Lahann, Joerg
- Licensing Officer: Schultz, Teri
Novel Therapeutic for Influenza-Induced Acute Respiratory Distress Syndrome
TS-032198 — A parenteral administration of a naturally occurring chemical used to treat influenza-induced hypoxemia, lung dysfunction, and acute respiratory distress syndrome (ARDS). This treatment could also be potentially useful in treating ARDS from other causes.
Acute respiratory distress syndrome (ARDS) is a clinical syndrome characterized by impaired alveolar gas exchange, a symptom that leads to a lack of oxygen in the bloodstream. This lack of oxygen to vital organs can lead to organ failure and results in a high possibility of patient death. The infl…
- College: College of Veterinary Medicine
- Inventors: Davis, Ian
- Licensing Officer: Dahlman, Jason "Jay"
Topical Compounds to Treat Leishmania
TS-014819 — A new class of drugs for the treatment of Leishmania.
Leishmaniasis is an infection caused by Leishmania parasites, spread by the bite of phlebotomine sand flies. It is prevalent in the tropics, subtropics, and southern Europe and is considered a neglected disease. Over a million people are infected with the parasite yearly, leading to skin sores and i…
- College: College of Medicine (COM)
- Inventors: Satoskar, Abhay; Fuchs, James; Isaac-Marquez, Angelica; Kinghorn, Alan "Dr. A. Douglas Kinghorn"; Lezama-Davila, Claudio; Pan, Li
- Licensing Officer: Schultz, Teri
